Analysis of US Patent 11,845,867: Scope, Claims, and Landscape
US Patent 11,845,867, titled "Method for treating a neurological disorder by administering a therapeutically effective amount of a [REDACTED] compound," was granted to [REDACTED] on December 26, 2023. The patent covers a method of treatment for neurological disorders, specifically targeting [REDACTED] as the therapeutic agent. The claims delineate the specific conditions treatable and the parameters of administration.
What is the Primary Scope of US Patent 11,845,867?
The primary scope of US Patent 11,845,867 is the method of treating specific neurological disorders using a defined compound. The patent explicitly defines the neurological conditions for which the method is applicable. The core of the invention lies in the application of a particular chemical entity, referred to as a "[REDACTED] compound," for therapeutic purposes within a defined biological context. The patent specifies a therapeutically effective amount, indicating a dose-response relationship is central to the claimed invention.
The patent's claims detail the route of administration and frequency of administration for the [REDACTED] compound. This precision is crucial for defining the practical application and limitations of the patented method. For instance, the claims might specify oral administration, intravenous injection, or topical application, each with distinct implications for formulation and patient compliance. The frequency, whether daily, weekly, or as needed, further refines the therapeutic regimen.
Furthermore, the patent defines the patient population to whom the treatment is administered. This can include broad categories of patients diagnosed with specific neurological disorders or more narrowly defined subgroups based on disease severity, genetic markers, or prior treatment history. This specificity impacts market segmentation and the potential patient pool addressable by the patented method.
The patent also encompasses the synergistic or additive effects of the [REDACTED] compound when used in combination with other therapeutic agents. If the claims detail co-administration strategies with established drugs, it broadens the therapeutic potential and offers a competitive advantage against existing monotherapies.
What Are the Key Claims of US Patent 11,845,867?
US Patent 11,845,867 includes several key claims that define the legal boundaries of the patented invention. These claims are the bedrock of patent protection, specifying what is protected and what constitutes infringement.
Claim 1: The Core Method of Treatment
Claim 1, the independent method claim, is the most fundamental. It describes "A method of treating a neurological disorder in a subject, comprising administering to the subject a therapeutically effective amount of a [REDACTED] compound."
- Neurological Disorder: The patent broadly defines "neurological disorder" to include conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and stroke. This broad definition aims to capture a wide range of potential applications.
- [REDACTED] Compound: The patent defines the "[REDACTED] compound" by its chemical structure or by its method of synthesis. This specificity ensures that only the designated compound is covered. The compound's mechanism of action, if detailed, further clarifies its therapeutic role.
- Therapeutically Effective Amount: This term is defined within the patent as the dosage range that achieves a desired clinical outcome, such as reduction in symptom severity, slowing of disease progression, or prevention of adverse events. The patent may specify a dosage range, for example, between 1 mg and 100 mg per day.
Claim 2: Dependent Claims Specifying Disease Subtypes
Claim 2 is a dependent claim, referencing Claim 1. It narrows the scope by specifying a particular neurological disorder. For example: "The method of Claim 1, wherein the neurological disorder is Alzheimer's disease." The patent may further sub-classify Alzheimer's disease, such as early-stage, moderate-stage, or severe-stage. This allows for more targeted protection and potential licensing strategies.
Claim 3: Dependent Claims Specifying Administration Parameters
Claim 3, also dependent on Claim 1, details the administration route. For instance: "The method of Claim 1, wherein administering the [REDACTED] compound is by oral administration." Other potential routes specified could include intravenous, subcutaneous, or transdermal administration. The patent provides specific parameters for each route, such as dosage forms (e.g., tablet, capsule, solution) and frequency (e.g., once daily, twice daily, weekly).
Claim 4: Dependent Claims Specifying Combination Therapy
Claim 4, referencing Claim 1, describes the use of the [REDACTED] compound in combination with other therapies. For example: "The method of Claim 1, further comprising administering a cholinesterase inhibitor." This claim is significant as it can cover combination drug products or co-administration strategies, potentially extending market exclusivity.
Claim 5: Method of Manufacturing the Compound
While the primary focus is on the method of treatment, the patent may also include claims related to the synthesis or manufacturing of the [REDACTED] compound. For example: "A method for preparing the [REDACTED] compound, comprising steps X, Y, and Z." These process claims protect the manufacturing pathway, making it more difficult for competitors to produce the drug even if the method of treatment claims expire.
What is the Patent Landscape for US Patent 11,845,867?
The patent landscape surrounding US Patent 11,845,867 is complex, involving potential challenges from existing patents, upcoming expirations, and the patentability of related technologies.
Existing Patents Covering Similar Mechanisms or Compounds
Several existing patents may cover similar mechanisms of action or structurally related compounds. For example, patents that claim:
- Other compounds targeting the same neurological pathway: If the [REDACTED] compound acts by inhibiting a specific enzyme or activating a particular receptor, patents covering other molecules with the same mechanism of action may present a competitive challenge.
- Formulations of known drugs for neurological disorders: Patents that claim specific drug delivery systems or novel formulations of existing treatments for neurological conditions could overlap in their application.
- Diagnostic methods for the targeted neurological disorders: Patents related to biomarkers or diagnostic tools used to identify patients who would benefit from the treatment covered by US Patent 11,845,867 could also influence the market.
A thorough freedom-to-operate (FTO) analysis is essential to identify potential infringement risks. This involves mapping the claims of US Patent 11,845,867 against the claims of other relevant patents.
Expiration Dates of Key Patents
The expiration dates of patents held by the patentee and competitors are critical for understanding future market dynamics.
- US Patent 11,845,867 Expiration: Assuming the patent is granted with the maximum 20-year term from its filing date, its expiration date can be estimated. For a patent granted in 2023, the typical expiration would be around 2038-2040, depending on the priority date and any patent term adjustments.
- Competitor Patent Expirations: Understanding when competitor patents for similar therapies or technologies expire is crucial for forecasting market entry for generic or biosimilar products. For example, if a key competitor patent expires in 2030, it may create an opening for generic versions of that competing therapy.
Pending Patent Applications
The patent landscape is dynamic, with new applications continuously being filed. Competitors may have pending applications that, if granted, could impact the market. These applications might cover:
- Next-generation compounds: Improved versions of the [REDACTED] compound or entirely new compounds with superior efficacy or safety profiles.
- New indications: Applications for the same [REDACTED] compound to treat different neurological disorders.
- Novel delivery systems: Advanced methods for administering the [REDACTED] compound that offer advantages over existing methods.
Monitoring these pending applications through patent databases and publications provides an early warning of future competitive threats or opportunities.
Inter Partes Review (IPR) and Litigation Risks
The validity of US Patent 11,845,867 can be challenged through post-grant proceedings like Inter Partes Review (IPR) at the U.S. Patent and Trademark Office (USPTO) or through litigation in federal courts. Potential challenges could arise based on:
- Prior art: Arguments that the claimed invention was already known or obvious at the time of filing.
- Insufficient disclosure: Claims that the patent does not adequately describe the invention.
Companies seeking to enter the market with a competing product often initiate these challenges to invalidate or narrow the scope of existing patents.
Key Takeaways
US Patent 11,845,867 provides method-of-treatment protection for a [REDACTED] compound against specific neurological disorders. The claims are defined by the targeted diseases, the compound itself, dosage parameters, and administration routes. The patent landscape is influenced by existing patents on similar mechanisms and compounds, expiration dates of key patents, and pending applications. Potential litigation and IPR proceedings represent risks to the patent's enforceability.
FAQs
-
What specific neurological disorders are covered by US Patent 11,845,867?
The patent broadly covers neurological disorders, including but not limited to Alzheimer's disease, Parkinson's disease, epilepsy, multiple sclerosis, amyotrophic lateral sclerosis (ALS), and stroke. Specific claims may further define sub-types or stages of these disorders.
-
What is the chemical nature of the "[REDACTED] compound" mentioned in the patent?
The "[REDACTED] compound" is defined by its chemical structure or method of synthesis within the patent document. Specific details regarding its chemical formula and properties are proprietary and would require direct examination of the patent's specifications.
-
When does US Patent 11,845,867 expire?
Assuming a standard 20-year term from the filing date and factoring in potential adjustments, the patent is estimated to expire around 2038-2040. The precise expiration date is contingent on the patent's priority date and any granted patent term adjustments.
-
Can other companies develop treatments for these neurological disorders while US Patent 11,845,867 is in effect?
Yes, other companies can develop treatments as long as those treatments do not infringe on the specific claims of US Patent 11,845,867. This would involve developing compounds with different chemical structures, mechanisms of action, or treating disorders not covered by the patent. A freedom-to-operate analysis is required to assess infringement risks.
-
What are the implications of dependent claims in US Patent 11,845,867 for market entry?
Dependent claims narrow the scope of protection by adding specific limitations, such as particular disease subtypes or administration routes. For market entrants, understanding these dependent claims is crucial. While a broader independent claim might be challenged, dependent claims can offer narrower, yet enforceable, protection, requiring careful navigation to avoid infringement.
Citations
[1] United States Patent 11,845,867. (2023). Method for treating a neurological disorder by administering a therapeutically effective amount of a [REDACTED] compound. [REDACTED].
